Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Phosphodiesterase (PDE) enzymes regulate intracellular signaling pathways crucial for brain development and the pathophysiology of neurological disorders. Among the 11 PDE subtypes, PDE4 and PDE5 are particularly significant due to their regulation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling, respectively, which are vital for learning, memory, and neuroprotection. This review synthesizes current evidence on the roles of PDE4 and PDE5 in neurological health and disease, focusing on their regulation of second messenger pathways and their implications for brain function. Elevated PDE4 activity impairs synaptic plasticity by reducing cAMP levels and protein kinase A (PKA) activity, contributing to cognitive decline, acute brain injuries, and neuropsychiatric conditions such as bipolar disorder and schizophrenia. Similarly, PDE5 dysregulation disrupts nitric oxide (NO) signaling and protein kinase G (PKG) pathways, which are involved in cerebrovascular homeostasis, recovery after ischemic events, and neurodegenerative processes in Alzheimer's, Parkinson's, and Huntington's diseases. PDE4 and PDE5 are promising therapeutic targets for neurological disorders. Pharmacological modulation of these enzymes offers potential to enhance cognitive function and mitigate pathological mechanisms underlying brain injuries, neurodegenerative diseases, and psychiatric disorders. Further research into the regulation of PDE4 and PDE5 will advance therapeutic strategies for these conditions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763391 | PMC |
| http://dx.doi.org/10.3390/cells14020086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel phosphodiesterase 4/5 dual-target inhibitor ameliorates neuroinflammation via the NF-κB and JNK pathway.
Int J Biol Macromol
July 2025
Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address:
Targeting neuroinflammation is a promising strategy for developing treatments for neurodegenerative diseases. Cyclic nucleotides like cAMP and cGMP, crucial second messengers in the central nervous system. Phosphodiesterases (PDEs) are the sole enzymes that hydrolyze these nucleotides in vivo.
View Article and Find Full Text PDFInhibition of PDE-4 and PDE-5 Differentially Modulates Isolated Porcine Urethral Contractility.
Int Urogynecol J
March 2025
Centre for Urology Research, Faculty of Health Sciences & Medicine, Bond University, 14 University Drive, Robina, Gold Coast, QLD, 4226, Australia.
Purpose/objective: This study explores the role of phosphodiesterase (PDE) inhibitors (specifically PDE-4, PDE-5 and PDE-1) in modulating the contractility of the porcine urethral smooth muscle and mucosal layers.
Methods: Using an organ bath setup, the effects of PDE inhibitors rolipram, roflumilast, sildenafil, tadalafil and vinpocetine (0.1 nM to 10 μm) on isolated porcine urethral mucosa-intact smooth muscle, mucosa-denuded smooth muscle and mucosal layers were investigated.
Modulation of Second Messenger Signaling in the Brain Through PDE4 and PDE5 Inhibition: Therapeutic Implications for Neurological Disorders.
Cells
January 2025
Department of Physiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Phosphodiesterase (PDE) enzymes regulate intracellular signaling pathways crucial for brain development and the pathophysiology of neurological disorders. Among the 11 PDE subtypes, PDE4 and PDE5 are particularly significant due to their regulation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling, respectively, which are vital for learning, memory, and neuroprotection. This review synthesizes current evidence on the roles of PDE4 and PDE5 in neurological health and disease, focusing on their regulation of second messenger pathways and their implications for brain function.
View Article and Find Full Text PDFDiscovery of a Phosphodiesterase 7A Inhibitor of High Isozyme Selectivity Exhibiting Anti-Osteoporotic Effects.
ACS Med Chem Lett
January 2025
Chemical Research Laboratories, i2i-Labo, Biological Pharmacological Research Laboratories, and Drug Metabolism & Pharma-cokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco, Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
Phosphodiesterases (PDEs) have drawn attention due to their critical roles in physiological and pathological conditions. Many research groups have studied these hydrolytic enzymes to develop new drugs, including apremilast as a PDE4 inhibitor and sildenafil as a PDE5 inhibitor. Targeting PDE7 has also been deemed a rational strategy to ameliorate autoimmune conditions.
View Article and Find Full Text PDFDiscovery and Optimization of Dihydroquinolin-2(1)-ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
J Med Chem
December 2024
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, P. R. China.
Article Synopsis
- A newly optimized compound showed potent inhibition of PDE5A with an impressive selectivity over other PDE enzymes, indicating strong potential as a treatment option.
- In animal studies, the compound outperformed sildenafil in reducing mean pulmonary artery pressure and right ventricle hypertrophy, suggesting it could be a promising new therapy for PAH.